These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2902420)

  • 1. Clinical spectrum of neuroleptic malignant syndrome.
    Clarke CE; Shand D; Yuill GM; Green MH
    Lancet; 1988 Oct; 2(8617):969-70. PubMed ID: 2902420
    [No Abstract]   [Full Text] [Related]  

  • 2. [Malignant neuroleptic syndrome. Treatment and resumption of the treatment in malignant neuroleptic syndrome].
    Pedersen S; Andreassen MD
    Ugeskr Laeger; 2000 Mar; 162(10):1411-2. PubMed ID: 10745687
    [No Abstract]   [Full Text] [Related]  

  • 3. Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms.
    Hernandez-Huerta D; Montes JM
    Prim Care Companion CNS Disord; 2018 Nov; 20(6):. PubMed ID: 30444963
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neuroleptic malignant syndrome--3 case reports].
    Simmich T; Müller J; Bach O
    Psychiatr Neurol Med Psychol (Leipz); 1990 Jun; 42(6):369-75. PubMed ID: 1976268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fulminant case of neuroleptic malignant syndrome.
    Teo SK; Lam KN; Chew WL
    Singapore Med J; 1994 Feb; 35(1):110-1. PubMed ID: 8009269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic toxicity syndromes: a clinical spectrum.
    Reilly JJ; Crowe SF; Lloyd JH
    Aust N Z J Psychiatry; 1991 Dec; 25(4):499-505. PubMed ID: 1686547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
    Sczesni B; Becker H; Schröder J; Bittkau S; von Baumgarten F; Truong DD; Przuntek H
    Wien Klin Wochenschr; 1991; 103(1):21-6. PubMed ID: 1673042
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical effects of abrupt neuroleptic withdrawal.
    Lacoursiere RB; Spohn HE; Thompson K
    Compr Psychiatry; 1976; 17(2):285-94. PubMed ID: 943275
    [No Abstract]   [Full Text] [Related]  

  • 9. Carbidopa/levodopa in the treatment of neuroleptic malignant syndrome.
    Shoop SA; Cernek PK
    Ann Pharmacother; 1997 Jan; 31(1):119. PubMed ID: 8997480
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome.
    Majic T; Mell T; Heinz A; Rapp MA
    Int Psychogeriatr; 2010 Jun; 22(4):678-9. PubMed ID: 20199702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroleptic malignant syndrome].
    Charra B; Nejmi H; Hachimi A; Benslama A; Motaouakkil S
    Ann Fr Anesth Reanim; 2006 May; 25(5):542-3. PubMed ID: 16488105
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride.
    Angelopoulos P; Markopoulou M; Kyamidis K; Bobotas K
    Gen Hosp Psychiatry; 2008; 30(5):482-4. PubMed ID: 18774435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance treatment of chronic schizophrenia with neuroleptic drugs.
    Morgan R; Cheadle J
    Acta Psychiatr Scand; 1974; 50(1):78-85. PubMed ID: 4207901
    [No Abstract]   [Full Text] [Related]  

  • 14. [Neuroleptic malignant syndrome--a case report on diagnosis, differential diagnosis and therapy of a life threatening complication of treatment with neuroleptics].
    Staud L; Pflug B
    Psychiatr Prax; 1992 Jul; 19(4):114-8. PubMed ID: 1354879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical picture and course of the neuroleptic malignant syndrome (acute febrile neuroleptic encephalopathy)].
    Avrutskiĭ GIa; Raĭskiĭ VA; Tsygankov BD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(9):1391-6. PubMed ID: 3425085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient.
    Ihara M; Kohara N; Urano F; Ichinose H; Takao S; Nishida T; Saiki H; Kawamoto Y; Ikeda A; Takagi S; Shibasaki H
    Neurology; 2002 Oct; 59(7):1102-4. PubMed ID: 12370475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Approach to resistance to treatment by neuroleptic combinations].
    Daskalopoulos NT; Cottereau MJ; Picchi E
    Ann Med Psychol (Paris); 1977 Jul; 2(2):333-51. PubMed ID: 596765
    [No Abstract]   [Full Text] [Related]  

  • 18. A curious case of neuroleptic malignant syndrome.
    Anand H; Spaner D
    Can J Psychiatry; 2004 Sep; 49(9):645-6. PubMed ID: 15503743
    [No Abstract]   [Full Text] [Related]  

  • 19. Frequency and presentation of neuroleptic malignant syndrome: a prospective study.
    Keck PE; Pope HG; McElroy SL
    Am J Psychiatry; 1987 Oct; 144(10):1344-6. PubMed ID: 2889378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
    Ladds B; Thomas P; Mejia C; Hauser D
    Am J Psychiatry; 2009 Jan; 166(1):114-5. PubMed ID: 19122020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.